USA

Through this agreement, Gilead now controls global rights to KT-200, an oral CDK2 molecular glue degrader designed to treat cancer.

AVS has developed the Pulse IVL system, which uses pressurised sound waves delivered through a balloon catheter to remove calcium deposits in patients with calcified peripheral artery disease (PAD).

The company receives USD10 million in near-term milestones and stands to earn up to USD 705 million additional milestone payments upon reaching key development and regulatory benchmarks.

C4 Therapeutics will use its proprietary TORPEDO platform to design the degrader payloads, while Roche will oversee antibody selection, conjugation chemistry, preclinical testing, and clinical development

The contract includes multiyear options that could ultimately deliver up to USD 482 million if exercised, enabling Shionogi to establish a dedicated manufacturing facility in the United States.

This setback follows Brinsupri’s unsuccessful phase 2 trial for chronic rhinosinusitis without nasal polyps, which also failed to meet its primary and secondary endpoints at both tested doses.

The Houston subsidiary will now serve as the strategic headquarters, overseeing and expanding collaborations with medical institutions and pharmaceutical companies across the United States.

Central to this deal is TSND-201, also known as methylone, Transcend’s lead experimental drug for post-traumatic stress disorder (PTSD) and other psychiatric conditions.

The acquisition grants Biogen access to two already-marketed medications that generated USD689 million in sales last year.

The Raptor™ platform uses advanced genetic engineering tools to produce recombinant biologics inside eggs.